exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087818 RNA Name: hsa-miR-181a-5p RNA Type: miRNA Chromosome: chr1 Starnd: - Coordinate: Start Site(bp): 198859108 End Site(bp): 198859130 External Links: hsa-miR-181a-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CDKN1B chr12 12715058 12722369 + ETS1 chr11 128458761 128587558 - GALNT10 chr5 154190730 154420984 + IGF2BP3 chr7 23310209 23470491 - IRS2 chr13 109752695 109786583 - LAMC1 chr1 183023420 183145592 + NFIB chr9 14081843 14398983 - PPP1R3C chr10 91628442 91633071 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001550 chr5 167915606 167921655 + hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001522 chr5 122881110 122893258 + hsa_circ_0000892 chr19 11941431 12014514 + hsa_circ_0001361 chr3 171830241 171851336 + hsa_circ_0000931 chr19 38226804 38231095 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC010442.1 chr5 466124 473098 - AC010655.4 chr7 128455840 128493859 + AC021078.1 chr5 149494314 149504670 - AC144548.1 chr12 110387463 110445548 - AL035458.2 chr20 34234840 34281173 - AL049543.1 chr6 28587378 28591747 + KCNQ1OT1 chr11 2608328 2699994 - LINC00667 chr18 5237826 5290608 + MALAT1 chr11 65497688 65506516 + MIR4458HG chr5 8450701 8486930 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + SNHG1 chr11 62851984 62855953 - SNHG5 chr6 85650491 85678932 - SNHG7 chr9 136721366 136728184 - THUMPD3-AS1 chr3 9349689 9398579 - XIST chrX 73820649 73852723 - ZSCAN16-AS1 chr6 28015122 28137293 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.